Kiji Therapeutics is developing a therapeutic to treat autoimmune diseases, using genetically engineered mesenchymal stem cells to improve potency and targeting. The drug is targeted towards patients with graft versus host disease, an autoimmune disease that occurs in bone marrow recipients. CEO Miguel Forte says the firm is exploring partnering with larger companies to commercialize its products. Earlier plans for a merger with Taiwanese company REGiMMUNE have been abandoned although other partnerships may be explored in future.
He downloaded a WhatsApp image. Minutes later, Rs 2 lakh was gone | Technology News
Pradeep Jain lost Rs 2.01 lakh from his bank account after hackers gained access to his phone through a scam using Least Significant Bit (LSB)
